Best Practices for Advancing Treatments in Newly Diagnosed and Relapsed/Refractory MM

Ajai Chari, MD, discusses the potential role for CAR T-cell therapies in the early-relapsed setting for patients with multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.